Article Access statistics

Viewed: 328

Emailed: 0

PDF Downloaded: 103

IP International Journal of Comprehensive and Advanced Pharmacology


Dyslipidemia in type 2 diabetes mellitus (T2dm): Pathophysiology, pattern and management


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : Dhanya A V, Sanjiv Karale*, Priya Varkey, Amruthakrishna Anil, Abhijith K

Volume : 4, Issue : 2, Year : 2019

Article Page : 34-38


Suggest article by email

Abstract

Type 2 diabetes mellitus (T2DM) is related with severe cardiovascular morbidity and mortality throughout the worldwide. Dyslipidemia, high blood glucose level, and coronary artery diseases are well linked with each other in T2DM and it has been demonstrated that higher prevalence of cardiovascular disease (CVD) in T2DM is due to chronic uncontrolled hyperglycemia. Dyslipidemia, which affects almost 50% of patients with T2DM, is a cardiovascular risk factor and characteristic features of dyslipidemic diabetes are elevated plasma triglyceride level, decline in high density lipoprotein cholesterol (HDL-c) level, and raised level of small dense low density lipoprotein (LDL) particles. An adequate availability of many lipid-lowering agents and nutritional supplements provides novel and effective treatments in control of lipid levels in diabetes patients. Several hypolipidemics, such as statins, fibric acid derivatives, niacin, and bile acid sequestrants, are available to target normalization of the entire lipid profile in T2DM patients. This review highlights the prevalence, underlying pathogenesis, patterns and various management approaches of dyslipidemia in patients with T2DM.

Keywords: Type 2 diabetes mellitus, Dyslipidemia, Cardiovascular disease, statins, Triglycerides.

Doi : 10.18231/j.ijcaap.2019.008

How to cite : Dhanya A V, Karale S, Varkey P, Anil A, Abhijith K, Dyslipidemia in type 2 diabetes mellitus (T2dm): Pathophysiology, pattern and management. IP Int J Compr Adv Pharmacol 2019;4(2):34-38

Copyright © 2019 by author(s) and IP Int J Compr Adv Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)